BlackRock Fund Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

BlackRock Fund Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$11K	Buy	87 +15	+21%	+$2.09K	﹤0.01%	3948
2016 Q3	$11K	Buy	72 +8	+13%	+$1.13K	﹤0.01%	3955
2016 Q2	$7K	Sell	64 -629	-91%	-$69.7K	﹤0.01%	4045
2016 Q1	$79K	Sell	693 -44	-6%	-$6.67K	﹤0.01%	3718
2015 Q4	$139K	Buy	737 +32	+5%	+$5.99K	﹤0.01%	3648
2015 Q3	$120K	Sell	705 -19	-3%	-$6.86K	﹤0.01%	3652
2015 Q2	$458K	Sell	724 -6,294	-90%	-$3.34M	﹤0.01%	3241
2015 Q1	$3.61M	Buy	7,018 +448	+7%	+$226K	﹤0.01%	2987
2014 Q4	$3.52M	Buy	6,570 +915	+16%	+$412K	﹤0.01%	3032
2014 Q3	$8.48M	Sell	5,655 -56	-1%	-$81.1K	﹤0.01%	2452
2014 Q2	$7.82M	Buy	5,711 +785	+16%	+$911K	﹤0.01%	2573
2014 Q1	$6.84M	Buy	4,926 +770	+19%	+$895K	﹤0.01%	2625
2013 Q4	$4.14M	Sell	4,156 -188	-4%	-$194K	﹤0.01%	2935
2013 Q3	$4.52M	Buy	4,344 +503	+13%	+$537K	﹤0.01%	2879
2013 Q2	$4.18M	Buy	+3,841	New	+$4.28M	﹤0.01%	2813

Other funds holding VIRX

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock Fund Advisors's VIRX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Viracta Therapeutics, Inc. Common Stock (VIRX) stake by 21% in Q4 2016, buying an estimated $2.09K and bringing the position to 87 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #3948.

BlackRock Fund Advisors first reported a position in VIRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $8.48M in Q3 2014. 45 funds tracked by Wall St. Rank hold VIRX as of Q4 2016.

BlackRock Fund Advisors held 87 shares of Viracta Therapeutics, Inc. Common Stock worth $11K as of Q4 2016.
BlackRock Fund Advisors bought 15 Viracta Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $2.09K.
Viracta Therapeutics, Inc. Common Stock made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3948 holding.
BlackRock Fund Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $8.48M in Q3 2014.
45 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.